-
公开(公告)号：US06451994B1
公开(公告)日：2002-09-17
申请号：US09406045
申请日：1999-09-27
IPC分类号： C07H2102
CPC分类号： C12N9/6472 , A01K2217/05 , A61K38/00 , A61K48/00
摘要： The present invention relates to a newly identified human ubiquitin protease belonging to the family of mammalian deubiquitinating enzymes. The invention also relates to polynucleotides encoding the ubiquitin protease. The invention further relates to methods using the ubiquitin protease polypeptides and polynucleotides as a target for diagnosis and treatment in ubiquitin-mediated or -related disorders. The invention further relates to drug-screening methods using the ubiquitin protease polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the ubiquitin protease polypeptides and polynucleotides. The invention further relates to procedures for producing the ubiquitin protease polypeptides and polynucleotides.
摘要翻译： 本发明涉及属于哺乳动物脱蛋白酶家族的新鉴定的人泛素蛋白酶。 本发明还涉及编码泛素蛋白酶的多核苷酸。 本发明还涉及使用泛素蛋白酶多肽和多核苷酸作为在泛素介导的或相关疾病中进行诊断和治疗的靶标的方法。 本发明还涉及使用泛素蛋白酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。 本发明还包括基于泛素蛋白酶多肽和多核苷酸的激动剂和拮抗剂。 本发明还涉及生产泛素蛋白酶多肽和多核苷酸的方法。
-
2.发明授权公开(公告)号：US06673564B2
公开(公告)日：2004-01-06
申请号：US09420190
申请日：1999-10-18
IPC分类号： C12Q144
摘要： The present invention relates to methods for using a human cyclic nucleotide phosphodiesterase belonging to the superfamily of mammalian phosphodiesterases. The invention also relates to methods for using polynucleotides encoding the phosphodiesterase. The invention relates to methods using the phosphodiesterase polypeptides and polynucleotides as a target for diagnosis and treatment in phosphodiesterase-mediated or -related disorders. The invention further relates to drug-screening methods using the phosphodiesterase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the phosphodiesterase polypeptides and polynucleotides. The invention further relates to agonists and antagonists identifiefd by drug screening methods with the phosphodiesterase polypeptides and polynucleotides as a target.
摘要翻译： 本发明涉及使用属于哺乳动物磷酸二酯酶超家族的人环状核苷酸磷酸二酯酶的方法。 本发明还涉及使用编码磷酸二酯酶的多核苷酸的方法。 本发明涉及使用磷酸二酯酶多肽和多核苷酸作为磷酸二酯酶介导的或相关疾病中的诊断和治疗的靶标的方法。 本发明还涉及使用磷酸二酯酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。 本发明还包括基于磷酸二酯酶多肽和多核苷酸的激动剂和拮抗剂。 本发明还涉及用磷酸二酯酶多肽和多核苷酸作为靶标的药物筛选方法鉴定的激动剂和拮抗剂。
-
3.发明授权21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor 失效21910,5563,4505,2504,15977,14760,25501,17903,3720,21529,26176,26343,5666,18610,33217,26967，H1983，M1983,38555或593分子及其用途公开(公告)号：US07696316B2
公开(公告)日：2010-04-13
申请号：US11583766
申请日：2006-10-19
申请人： Rosana Kapeller-Libermann , John Joseph Hunter , Rachel E. Meyers , Laura A. Rudolph-Owen , Rory A. J. Curtis , Peter J. Olandt , Fong-Ying Tsai , Katherine M. Galvin , Miyoung Chun , Mark J. Williamson , Inmaculada Silos-Santiago , Rajasekhar Bandaru
发明人： Rosana Kapeller-Libermann , John Joseph Hunter , Rachel E. Meyers , Laura A. Rudolph-Owen , Rory A. J. Curtis , Peter J. Olandt , Fong-Ying Tsai , Katherine M. Galvin , Miyoung Chun , Mark J. Williamson , Inmaculada Silos-Santiago , Rajasekhar Bandaru
CPC分类号： C07K14/47 , A01K2217/05 , C12N9/1235
摘要： The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供分离的核酸分子，命名为21910,5663,55053,2504,15977,14760,25501,17903,3720,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,38555和593核酸 分子。 本发明还提供反义核酸分子，含有21910,5663,55053,2504,15977,14760,25501,17903,3700,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,3855的重组表达载体 和593个核酸分子，其中引入了表达载体的宿主细胞，以及非人类转基因动物，其中21910,5663,5553,2504,15977,14760,25501,17903,3720,21529,26176， 已经引入或破坏了18610,33217,21967，h1983，m1983,38555或593基因。 本发明还进一步提供分离的21910,5563,4560,25501,17903,3720,21529,26176,26343,5663,18610,33217,21967，h1983，m1983,38555或593蛋白，融合蛋白， 抗原肽和抗-19910,563634,55053,2504,15977,14760,25501,17903,3720,21529,26176,26343,56638,18610,33217,21967，h1983，m1983,38555或593抗体。 还提供了利用本发明组合物的诊断和治疗方法。
-
4.发明申请Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor 失效小分子13237,18480,2245,16228,7677,26320,46169,36166,16836,46867,21617,55562,39228,62088,4675,23155,26657,42755,32229,22325,46863和32252分子及其用途公开(公告)号：US20090263860A1
公开(公告)日：2009-10-22
申请号：US11980299
申请日：2007-10-30
申请人： Rachel E. Meyers , Mark J. Williamson , Rosana Kapeller-Libermann , Kyle J. MacBeth , John Joseph Hunter , Laura A. Rudolph-Owen , Rajasekhar Bandaru , Fong-Ying Tsai
发明人： Rachel E. Meyers , Mark J. Williamson , Rosana Kapeller-Libermann , Kyle J. MacBeth , John Joseph Hunter , Laura A. Rudolph-Owen , Rajasekhar Bandaru , Fong-Ying Tsai
CPC分类号： C12N9/1205 , A01K2217/05 , A61K48/00 , C07K2319/00
摘要： The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供分离的核酸分子，命名为13237,18480,2225,16228,7677,26320,4619,33166,16836,46867,21617,55562,39228,62088,46745,23155,21657,42755,32229,22325,46863 和32252个核酸分子。 本发明还提供反义核酸分子，重组表达载体，其含有13237,18480,2245,16228,7677,26320,4619,33166,16836,46867,21617,55562,39228,62088,46745,23155,216575,42755,32229 ，22325,46863和32252核酸分子，其中引入了表达载体的宿主细胞，以及非人类转基因动物，其中13237,18480,2362,46169,3677,26320,46869,38166,16836,46867,21617,26173,26169， 已经引入或破坏了55562,39228,62088,4675,23155,21657,42755,32229,22325,46863或32252基因。 本发明还进一步提供分离的13237,18480,2225,16228,7677,26320,4619,33166,16836,46867,21617,55562,39228,62088,46745,23155,21657,42755,32229,22325,46863或32252蛋白质 ，融合蛋白，抗原肽和抗-13237,18480,2225,16228,7677,26320,4619,33166,16836,46867,21617,55562,39228,62088,46745,23155,216547,42755,32229,22325,46863 或32252抗体。 还提供了利用本发明组合物的诊断和治疗方法。
-
公开(公告)号：US09458202B2
公开(公告)日：2016-10-04
申请号：US12625533
申请日：2009-11-24
申请人： Huw M. Nash , David Allen Annis , Rosana Kapeller-Libermann , Tomi K. Sawyer , Noriyuki Kawahata
发明人： Huw M. Nash , David Allen Annis , Rosana Kapeller-Libermann , Tomi K. Sawyer , Noriyuki Kawahata
CPC分类号： G01N33/68 , A61K31/02 , C07K2/00 , C07K14/001 , C07K14/4705 , C07K14/4747 , C07K14/4748
摘要： The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
摘要翻译： 本发明提供了相对于其相应多肽具有改进性质的生物活性的拟肽大环化合物。 本发明另外提供了制备和使用这种大环化合物的方法，例如在治疗应用中。
-
公开(公告)号：US20130072439A1
公开(公告)日：2013-03-21
申请号：US13497522
申请日：2010-09-22
申请人： Huw M. Nash , Rosana Kapeller-Libermann , Jia-wen Han , Tomi K. Sawyer , Justin Noehre , Noriyuki Kawahata
发明人： Huw M. Nash , Rosana Kapeller-Libermann , Jia-wen Han , Tomi K. Sawyer , Justin Noehre , Noriyuki Kawahata
摘要： Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an a,a-disubstituted amino acid, or may comprise a crosslinker linking the a-positions of at least two amino acids or at least one of said two amino acids may be an a,a-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.
摘要翻译： 公开了包含螺旋的拟肽大环化合物，例如α螺旋，以及使用这种大环化合物治疗诸如癌症的疾病的方法。 在其它方面，拟肽大环化合物包含a，α-二取代的氨基酸，或可以包含连接至少两个氨基酸的a-位的交联剂或所述两个氨基酸中的至少一个可以是a， 氨基酸。 进一步包括靶向Wnt信号通路的组分，例如Tcf4- / 3-连环蛋白复合物。
-
7.发明申请HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR 审中-公开人类胆固醇ACYLTRANSFERASE 2（DGAT2）家族成员及其用途公开(公告)号：US20120177661A1
公开(公告)日：2012-07-12
申请号：US13424574
申请日：2012-03-20
IPC分类号： A61K39/395 , C12N5/10 , C12N1/21 , C12N1/19 , C12N9/10 , C07K16/40 , G01N33/566 , C12N9/96 , C12Q1/48 , C12Q1/68 , C12N9/99 , C12N5/071 , A61K38/45 , A61P3/04 , A61P3/06 , C12N15/54
CPC分类号： C12N9/1029 , A01K2217/05 , C07K16/40 , C12Q1/48 , C12Y203/0102 , G01N33/573 , G01N2333/91051 , G01N2800/044
摘要： The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
摘要翻译： 本发明涉及用于诊断和治疗肥胖症及相关代谢紊乱的组合物和方法。 本发明提供编码二酰基甘油酰基转移酶家族成员的分离的核酸分子，称为DGAT2家族成员核酸分子。 本发明还提供了含有DGAT2家族成员核酸分子的重组表达载体，已引入表达载体的宿主细胞，以及导入或破坏了DGAT2家族成员基因的非人类转基因动物。 本发明还进一步提供分离的DGAT2家族成员蛋白，融合蛋白，抗原肽和抗DGAT2家族成员抗体。 还公开了所提供的DGAT2家族成员组合物用于与肥胖症有关的筛选，诊断和治疗方法的方法。
-
公开(公告)号：US20090326192A1
公开(公告)日：2009-12-31
申请号：US12420816
申请日：2009-04-08
申请人： Huw M. Nash , Rosana Kapeller-Libermann , Tomi K. Sawyer , Noriyuki Kawahata , Vincent Guerlavais , Matthew Iadanza
发明人： Huw M. Nash , Rosana Kapeller-Libermann , Tomi K. Sawyer , Noriyuki Kawahata , Vincent Guerlavais , Matthew Iadanza
IPC分类号： C07K2/00
CPC分类号： C07K7/56 , C07K1/1077 , C07K1/113 , C07K1/1136 , G01N33/68 , G01N2500/04
摘要： The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
摘要翻译： 本发明提供了相对于其相应多肽具有改进性质的生物活性的拟肽大环化合物。 本发明另外提供了制备和使用这种大环化合物的方法，例如在治疗应用中。
-
9.发明授权26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor 有权26199,33530,3949,47148,50226,58764,612113,32144,32235,23565,13305,14911,86216,25206和8843分子及其用途公开(公告)号：US07485308B2
公开(公告)日：2009-02-03
申请号：US11493347
申请日：2006-07-26
申请人： Rachel E. Meyers , Kyle J. MacBeth , Rory A. J. Curtis , Laura A. Rudolph-Owen , Nadine S. Weich , Peter J. Olandt , Fong-Ying Tsai , Rosana Kapeller-Libermann , Joseph M. Carroll
发明人： Rachel E. Meyers , Kyle J. MacBeth , Rory A. J. Curtis , Laura A. Rudolph-Owen , Nadine S. Weich , Peter J. Olandt , Fong-Ying Tsai , Rosana Kapeller-Libermann , Joseph M. Carroll
CPC分类号： C12N9/001 , A01K2217/05 , A01K2217/075 , A61K38/00 , A61K48/00 , C07K2319/00 , C12N9/0006 , C12N9/10 , C12N9/1048 , C12N9/1096 , C12N9/12 , C12N9/1205 , C12N9/16 , C12N9/48 , C12N9/80 , C12N2799/021 , C12Q1/32 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57449 , G01N2500/10 , Y10T436/143333
摘要： The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供分离的核酸分子，命名为26199,33530,3399,47148,50226,58764,62113,32144,32235,23565,13305,14911,86216,25206和8843核酸分子。 本发明还提供反义核酸分子，包含26199,33530,3399,47148,50226,58764,62113,32144,32235,23565,13305,14911,86216,25206和8843核酸分子的重组表达载体，其中宿主细胞 已经引入了表达载体，并且已引入或破坏其中26199,33530,3399,47148,50216,58764,62113,32144,32235,23565,13305,14911,86216,25206或8843基因的非人转基因动物。 本发明还进一步提供了分离的26199,33530,3949,47148,50226,58764,62113,32144,32235,23565,13305,14911,86216,25206或8843蛋白，融合蛋白，抗原肽和抗-26199,33530,3399 ，47148,50226,58764,62113,32144,32235,23565,13305,14911,86216,25206或8843抗体。 还提供了利用本发明组合物的诊断和治疗方法。
-
公开(公告)号：US07410785B2
公开(公告)日：2008-08-12
申请号：US11325013
申请日：2006-01-04
CPC分类号： C12N9/1029 , A61K38/00 , C12Y203/01015
摘要： The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要翻译： 本发明提供编码新的酰基转移酶家族成员的分离的核酸分子，命名为ACTR-1核酸分子。 本发明还提供了反义核酸分子，含有ACTR-1核酸分子的重组表达载体，其中引入了表达载体的宿主细胞和其中引入或破坏了ACTR-1基因的非人类转基因动物。 本发明还进一步提供了分离的ACTR-1蛋白，融合蛋白，抗原肽和抗ACTR-1抗体。 还提供了利用本发明组合物的诊断方法。
-
-
-
-
-
-
-
-
-
搜索结果
100 条记录 (耗时 0.052 秒)
